BrainStorm wants to hear from you! Send us a text.

 Alzheimer’s is being singled out in Medicare’s decision on reimbursement for patients. President of Global Alzheimer’s Platform Foundation and Co-Founder of UsAgainstAlzheimer’s, John Dwyer spoke with host Meryl Comer about the ramification to patients and how this decision will create greater disparities. Take a listen.

This episode is sponsored by Genentech and Eisai. 

Support the show

BrainStorm wants to hear from you! Send us a text.

We the Scientists: How a Daring Team of Parents and Doctors Forged a New Path for Medicine

In Part 2 of the interview with Amy Dockser Marcus, Pulitzer Prize winning Wall Street Reporter and Author, she and host Meryl Comer discuss a rare disease often likened to Children’s Alzheimer’s.  The common thread is advancing the science with new pathways for treating disease and conducting research. Amy talks about if this new collaborative research model aimed at saving children would work for elderly populations with long-term chronic diseases like Alzheimer’s. In the process to accelerate new drug development, science may be forever changed. 

This episode is sponsored by Genentech and Eisai.

If you have recommendations for topics or guests, email us at [email protected]. To learn more go to: https://www.usagainstalzheimers.org/

Support the show

BrainStorm wants to hear from you! Send us a text.

We the Scientists: How a Daring Team of Parents and Doctors Forged A New Path for Medicine

 Pulitzer Prize winning Wall Street Reporter Amy Marcus, in her new book We the Scientists, discusses a rare disease often likened to Children’s Alzheimer’s with BrainStorm host, Meryl Comer. Not only are the patients young, but their parents are desperate to help scientists find a drug to slow disease progression to extend their lives. Most children, born seemingly normal, rarely live beyond the age of 20. The common thread is advancing the science with new pathways for treating disease and conducting research. In the process to accelerate new drug development, science may be forever changed.

This episode of BrainStorm is sponsored by Genentech and Eisai.

For more information about this episode and a search to cure Alzheimer's go to UsAgainstAlzheimers.org

Support the show

BrainStorm wants to hear from you! Send us a text.

Want to improve your brain’s performance? Find out the latest from Dr. Sandra Bond Chapman, Founder and Chief Director of The Center for BrainHealth at the University of Texas at Dallas. In this episode Dr. Chapman talks about progress on the world’s largest brain health study to measure improvements after training the brain.  No matter what your age, learn to maximize your cognitive potential to be as sharp as you were in your 30s and 40s.

This episode of BrainStorm is sponsored by Genentech and Eisai.

For more information about this episode and a search to cure Alzheimer's go to UsAgainstAlzheimers.org

Support the show

BrainStorm wants to hear from you! Send us a text.

Want to improve your brain’s performance? Why not? You’re using it anyway. Find out the latest from Dr. Sandi Bond Chapman, Founder and Chief Director of The Center for BrainHealth at the University of Texas at Dallas. In this episode Dr. Chapman talks about how to maximize your cognitive potential with the goal, no matter what your age, to be as sharp as you were in your 30s and 40s. To learn more about BrainStorm go to usagainstalzheimers.org.

This Episode of BrainStorm is sponsored by Genentech.

Support the show

BrainStorm wants to hear from you! Send us a text.

Rebecca Chopp, Ph.D., built a life around a profession that prized the mind and then was unexpectedly diagnosed with Alzheimer's disease. Dr. Chopp, former Chancellor of the University of Denver, President of Swarthmore College and Colgate University, and Dean and Professor of Theology at Yale Divinity School, talks with Meryl Comer about the role of spirituality and emancipatory transformation in managing life through the prism of her early onset of Alzheimer’s disease. 

Support the show

BrainStorm wants to hear from you! Send us a text.

Rebecca Chopp, Ph.D., built a life around a profession that prized the mind and then was unexpectedly diagnosed with Alzheimer's disease. Hear how Dr. Chopp, former Chancellor of the University of Denver, President of Swarthmore College and Colgate University, and Dean and Professor of Theology at Yale Divinity School, learned to embrace joy after coming to terms with her Alzheimer’s diagnosis.  

Support the show

BrainStorm wants to hear from you! Send us a text.

BrainStorm host Meryl Comer talks with Dr. Rudy Tanzi, Vice-Chair of Neurology at Massachusetts General Hospital, Co-Director of the McCance Center for Brain Health and Professor at Harvard Medical School.  Hear what Dr. Tanzi discovered through his creative collaboration on 4 books with integrative medicine guru, Deepak Chopra, and his action plan "SHIELD" to offset the risk of Alzheimer’s disease.

Support the show

BrainStorm wants to hear from you! Send us a text.

Will 2023 be a boom or bust year for new Alzheimer’s drugs? 

In this episode of BrainStorm host Meryl Comer talks with Dr. Rudy Tanzi, Vice-Chair of Neurology at Massachusetts General Hospital, Co-Director of the McCance Center for Brain Health and Professor at Harvard Medical School.  Dr. Tanzi discusses the promising new drugs in a highly charged scientific environment and how these drugs have opened the door to advancement in the treatment of Alzheimer’s. 

Support the show

BrainStorm wants to hear from you! Send us a text.

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?

In this episode of BrainStorm host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative. They explore the implications of the approval of Lecanemab (or Leqembi) worldwide and whether the approval encourages healthy at-risk adults 50 plus to understand their dementia risk profile.

Support the show